Eli Lilly (NYSE: LLY) is getting a lot of Wall Street attention again. Its stock has skyrocketed 180% in the last three years, with a slew of its medicines hitting the market and a flurry of promising readouts from late-stage clinical trials.

But smart investors know that past performance doesn't necessarily predict future returns. That's why if you're thinking about buying the stock, you should first appreciate these three key insights about this pharmaceutical giant.

Eli Lilly's drug development pipeline is as big as they come, and that means plenty of new medicines are likely to hit the market in any given period. In fact, right now the business has four different drugs are in the last stage of regulatory approval, and each of them could find traction in huge markets.

Continue reading

Source Fool.com